Using GSK3 inhibitors, we previously showed that the correction of the GSK3β-CUGBP1 pathway reduces the muscle phenotype in HSALR mice [20], a model for adult, classic DM1 expressing CUG repeats in skeletal muscle [24]. This evidence concerns the gene GSK3B and myotonic dystrophy type 1.